Search results for " contraception"

showing 10 items of 21 documents

Hormonālās kontracepcijas lietošanas ietekme uz premenstruālajiem simptomiem studējošo sieviešu populācijā Rīgā, Latvijā

2018

Premenstrual syndrome (PMS) is an underdiagnosed condition in many women, which is related to a high risk of chronic pain and depression. PMS is difficult to diagnose as it remains different in every individual and does not show typical clinical signs.We combined similar symptoms to five kinds of PMS (psychological, equilibrium change, mental, physical, organ-specific) and further combined all kinds of together to obtain a total PMS for each woman. We checked univariate relationships between kind of contraceptives used by females and different kinds of PMS and total PMS. Most of PMS occur in the week before period in comparison with the week after a period, and this difference was significa…

Intrauterine Devicepremenstruālie simptomiHormonal ContraceptionMedicīnaPremenstrual symptoms
researchProduct

A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Cons…

2015

Abstract Background: Female sex hormones are known to have immunomodulatory effects. Therefore, reproductive factors and exogenous hormone use could influence the risk of multiple myeloma in women. However, the role of hormonal factors in multiple myeloma etiology remains unclear because previous investigations were underpowered to detect modest associations. Methods: We conducted a pooled analysis of seven case–control studies included in the International Multiple Myeloma Consortium, with individual data on reproductive factors and exogenous hormone use from 1,072 female cases and 3,541 female controls. Study-specific odds ratios and corresponding 95% confidence intervals (CI) were estima…

MaleEpidemiologymedicine.medical_treatmentPhysiology[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineRisk FactorsOdds RatioGonadal030212 general & internal medicineReproductive HistoryMultiple myelomaIncidenceMiddle AgedStatisticalPrognosis3. Good healthPostmenopauseContraceptionOncologyTransgender hormone therapy030220 oncology & carcinogenesisMeta-analysisRegression AnalysisFemaleMultiple MyelomaFactor AnalysisAdultHormone Replacement Therapy[SDV.CAN]Life Sciences [q-bio]/CancerArticle03 medical and health sciencesYoung AdultMeta-Analysis as TopicReproductive factors exogenous hormone use and risk of multiple myelomamedicineConfidence IntervalsHumansNeoplasm StagingSteroid Hormonesbusiness.industryCase-control studyOdds ratiomedicine.diseaseHormonesLogistic ModelsHormonal contraceptionCase-Control StudiesSample SizeImmunologyHormone therapybusinessHormoneFollow-Up StudiesMeta-Analysis
researchProduct

2021

ObjectiveLoss of sex hormones has been suggested to underlie menopause-associated increment in cardiovascular risk. We investigated associations of sex hormones with arterial stiffness in 19–58-years-old women. We also studied associations of specific hormonal stages, including natural menstrual cycle, cycle with combined oral contraceptives (COC) and menopausal status with or without hormone therapy (HT), with arterial stiffness.MethodsThis study includes repeated measurements of 65 healthy women representing reproductive (n=16 natural, n=10 COC-users) and menopause (n=5 perimenopausal, n=26 postmenopausal, n=8 HT-users) stages. Arterial stiffness outcomes were aortic pulse wave velocity (…

Mean arterial pressurebusiness.industryEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectmedicine.medical_treatmentPhysiologymedicine.diseaseMenopauseHormonal contraceptionTransgender hormone therapyArterial stiffnessMedicineHormone therapybusinessPulse wave velocityMenstrual cyclemedia_commonFrontiers in Endocrinology
researchProduct

Estroprogestins and cardiovascular risk in Polycystic Ovary Syndrome

2013

Because PCOS women present an increased cardiovascular risk, the safety of estroprogestin treatment is debated and contrasting data have been reported. However, cardiovascular risk is not the same in all PCOS women and individual cardiovascular risk should be assessed before staring any estroprogestin treatment. The available data show that products containing both second generation and third generation progestins (including drosperinone and cyproterone acetate) represent a safe treatment in PCOS patients with regular cardiovascular risk. In PCOS patients with increased cardiovascular risk, a careful choice of estroprogestin product is needed and cardiovascular risk should be monitored duri…

PCOS Estroprogestins Cardiovascular risk contraception hyperandrogenismSettore MED/40 - Ginecologia E OstetriciaSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/13 - Endocrinologia
researchProduct

La objeción de conciencia farmacéutica a la píldora postcoital

2003

The article represents a taking of position regarding the matter of the conscience objection towards the morning-after pill (MAP). The MAP is considered like an emergency contraception that the woman can take within the 72 hours from the sexual intercourse. The mechanisms of action of the product can be the following: a. to avoid the ovulation; b. to prevent the fusion between oocyte and sperm after the ovulation; c. to make impossible the implant of the embryo in the uterus. The author questions in the article if the MAP is abortive and, in this case, explicits the fundamental points of the Spanish law about the conscience objection. It is not difficult to ascertain that the MAP acts as co…

Pregnancybusiness.industryHealth Policymedia_common.quotation_subjectmedicine.medical_treatmentMedicine (miscellaneous)Abortionmedicine.diseasePhilosophyIssues ethics and legal aspectsSexual intercoursePosition (obstetrics)Action (philosophy)LawMedicineEmergency contraceptionbusinessOvulationConsciencemedia_commonMedicina e Morale
researchProduct

Optimal management of hormonal contraceptives after an episode of venous thromboembolism

2019

Optimal management of hormonal contraception in patients with venous thromboembolism (VE) requires an individualized approach considering its potential benefits and complications during and after anticoagulant treatment. Potential benefits include prevention of pregnancy and mitigation of menstrual bleeding that is often worsened after start of anticoagulation therapy. Current evidence suggests that patients may opt for a continuation of (all forms of) hormonal contraception during anticoagulant treatment, provided that they are adequately informed by the treating physicians. Combined oral contraceptives should be stopped before anticoagulant therapy may he discontinued, preferably after th…

Quality of lifemedicine.medical_specialtymedia_common.quotation_subjectHormonal contraception030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeHumansMedicineIntensive care medicineMenstrual cyclemedia_commonPregnancybusiness.industryMenstrual bleedingAnticoagulantsHematologymedicine.diseaseOptimal managementContraceptives Oral CombinedMenstrual bleedingHormonal contraception030220 oncology & carcinogenesisFemalebusinessVenous thromboembolismHormoneVenous thromboembolism
researchProduct

AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)

2016

After the first successful pregnancy in a liver transplant recipient in 1978, much evidence has accumulated on the course, outcomes and management strategies of pregnancy following liver transplantation. Generally, liver transplantation restores sexual function and fertility as early as a few months after transplant. Considering that one third of all liver transplant recipients are women, that approximately one-third of them are of reproductive age (18-49 years), and that 15% of female liver transplant recipients are paediatric patients who have a >70% probability of reaching reproductive age, the issue of pregnancy after liver transplantation is rather relevant, and obstetricians, paedi…

Risk AssessmentFertility; Immunosuppression; Liver transplantation; PregnancyImmunosuppressive AgentPregnancyMedicalFertility; Immunosuppression; Liver transplantation; Pregnancy; Hepatology; GastroenterologyHumansFertility; Immunosuppression; Liver transplantation; Pregnancy; Gastroenterology; HepatologyObstetric Labor ComplicationSocieties MedicalLiver transplantationHepatologyPostpartum PeriodPregnancy OutcomeGastroenterologyFertility; Immunosuppression; Liver transplantation; Pregnancy; Contraception; Female; Fertility; Gastroenterology; Humans; Italy; Obstetric Labor Complications; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Risk Assessment; Societies Medical; Immunosuppressive Agents; Liver Transplantation; Pregnancy OutcomeFertility; Immunosuppression; Liver transplantation; Pregnancy; Contraception; Female; Fertility; Gastroenterology; Humans; Italy; Obstetric Labor Complications; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Risk Assessment; Societies Medical; Immunosuppressive Agents; Liver Transplantation; Pregnancy Outcome; Hepatology; GastroenterologyPregnancy ComplicationObstetric Labor ComplicationsPregnancy ComplicationsContraceptionFertilitysurgical procedures operativeItalyPractice Guidelines as TopicFemaleSocietiesImmunosuppressive AgentsImmunosuppressionHuman
researchProduct

Consensus On Women'S Health Aspects Of Polycystic Ovary Syndrome (Pcos)

2012

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females with a high prevalence. The etiology of this heterogeneous condition remains obscure and its phenotype expression varies. Two, widely cited, previous ESHRE/ASRM-sponsored PCOS consensus workshops focused on diagnosis (published in 2004) and infertility management (published in 2008). The present third PCOS consensus paper summarizes current knowledge and identifies knowledge gaps regarding various women's health aspects of PCOS. Relevant topics addressed-all dealt with in a systematic fashion-include adolescence, hirsutism and acne, contraception, menstrual cycle abnormalities, quality of life, ethnicity, preg…

Settore MED/09 - Medicina InternaConsensus Development Conferences as TopicmenopauseType 2 diabetesSettore MED/13 - EndocrinologiaQuality of lifecancer; cardiovascular disease; contraception; hirsutism; insulin resistance; menopause; PCOS; pregnancy; quality of life; type 2 diabetescardiovascular diseaseNeoplasmsinsulin resistancePCOShirsutismhirsutismReproductive BiologyPolycystic ovary syndrome (PCOS)RehabilitationObstetrics and GynecologyObstetrics & GynecologyMiddle AgedMenopausePhenotypecontraceptionCardiovascular DiseasesPCOS Cardiovascular risk adolescence cancer obesityFemalepregnancytype 2 diabetesPolycystic Ovary SyndromeAdultmedicine.medical_specialtyConsensusAdolescentDiabetes ComplicationsInsulin resistanceSDG 3 - Good Health and Well-beingmedicineHumanscancerMenstrual CycleAgedGynecologyPregnancybusiness.industryCancermedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaReproductive MedicineDiabetes Mellitus Type 2quality of lifeWomen's Healthbusiness
researchProduct

La vasectomia a sostegno del piacere: analisi casistica e considerazioni medico legali

2012

In Italy, the resort to vasectomy, surgery adapted to determine an irreversible alteration of the physical state of an individual, resulting in the loss of the ability to procreate, is somewhat reduced compared to the others European countries, even though legitimate, it carries the disadvantage of the absence of a clear and univocal legislation concerning surgical sterilization. Despite, in recent years there has been a change in the assessment of such surgery. Nevertheless, is relevant that in the Italian legal system still lacks a regulatory of such medical-surgery activities, although several bills have been submitted to the competent parliamentary bodies. The attitude of indifference t…

Settore MED/43 - Medicina Legalevasectomy male contraception voluntary sterilization consent
researchProduct

Predicting the age at natural menopause in middle-aged women

2021

Objective To predict the age at natural menopause (ANM). Methods Cox models with time-dependent covariates were utilized for ANM prediction using longitudinal data from 47 to 55-year-old women (n = 279) participating in the Estrogenic Regulation of Muscle Apoptosis study. The ANM was assessed retrospectively for 105 women using bleeding diaries. The predictors were chosen from the set of 32 covariates by using the lasso regression (model 1). Another easy-to-access model (model 2) was created by using a subset of 16 self-reported covariates. The predictive performance was quantified with c-indices and by studying the means and standard deviations of absolute errors (MAE ± SD) between the pre…

final menstrual periodelintavatvaihdevuodetAlcohol DrinkingGeneral MathematicsConcordancemedia_common.quotation_subjectkeski-ikäkuukautiset030209 endocrinology & metabolismOriginal Studies03 medical and health sciencesMenopause prediction0302 clinical medicineSex hormone-binding globulinCovariateHumansMedicineMenopausal transitiontilastolliset mallitSocioeconomic statusMenstrual CycleMenstrual cycleProportional Hazards ModelsRetrospective Studiesmedia_commonperimenopause030219 obstetrics & reproductive medicinebiologyVasomotorbusiness.industryProportional hazards modelpremenopause.Applied Mathematicsmenopausal transitionObstetrics and GynecologyennusteetMiddle AgedPerimenopausePremenopauseHormonal contraceptionbiology.proteinFinal menstrual periodFemaleMenopausebusinessmenopause predictionDemographyMenopause
researchProduct